Neoadjuvant Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Stages IB, IIA, IIB, and IIIA/T3

Phase 3TerminatedNCT00273507

Rigshospitalet, Denmark270 enrolled

Overview

Randomised trial of chemotherapy or not before surgery in early resectable stages of NSCLC (IB, IIA, IIB, and IIIA/N2).

Randomisation between 3 courses of neoadjuvant Carboplatin plus Paclitaxel or no chemotherapy before surgery.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

270

Conditions

Non-small Cell Lung Cancer

Interventions

Carboplatin and PaclitaxelDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * NSCLC * Stages IB, IIA, IIB, IIIA/T3 * Lung function test allowing surgery * Age 18-75 years Exclusion Criteria: * Poor lung function * Performance status 3-4 * Mediastinal lymph node involvement

Locations (1)

Dept. Oncology, Rigshospitalet

Copenhagen, Copenhagen, Denmark

Outcomes

Primary Outcomes

Survival

Secondary Outcomes

Time to progression

Complete resection rate

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.